We further performed an assessment of DON against NBL and EWS tumors to determine whether targeting glutamine metabolism is a viable therapeutic approach that should be pursued for neuroblastoma (NBL) and Ewing’s sarcoma (EWS). This evidence concerns the gene EWSR1 and Ewing sarcoma.